Metabolism and disposition of GTS-21, a novel drug for Alzheimer's disease

References

• AZUMA, R., MINI, Y. and SATOH, T., 1996, Simultaneous determination of GT S-21 and its metabolite in rat plasma by high-performance liquid chromatography using solid-phase extraction. Journal of Chromatography B: Biomedical applications, 686, 229–234.
   Web of Science ®Google Scholar
• BALDWIN, S. J., BLOOMER, J. C., SMITH, G. J., AYRTON, A. D., CLARICE, S. E. and CHENERY, R. J., 1995, Ketoconazole and sulphaphenazole as the respective selective inhibitors of CYP3A and CYP2C9. Xenobiotka, 25, 261–270.
   PubMed Web of Science ®Google Scholar
• BAX, A. and SUMIVIERS, M. F., 1986,11-1 and 13C assignments from sensitivity-enhanced detection of heteronuclear multiple-bond connectivity by 2D multiple quantum NMR. Journal of American Chemical Society, 108, 2093–2094.
   Web of Science ®Google Scholar
• CHANG, T. K., GONZALEZ, F. J. and WAXMAN, D. J., 1994, Evaluation of triacetyloleandomycin, a-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Archives of Biochemistry and Biophysics, 311, 437–442.
   PubMed Web of Science ®Google Scholar
• CLARICE, S. E., AYRTON, A. D. and CHENERY, R. J., 1994, Characterization of the inhibition of P4501A2 by furafylline. Xenobiotka, 24, 517–526.
   PubMed Web of Science ®Google Scholar
• DE FIEBRE, C. M., MAYER, E. M., HENRY, J. C., MURASKIN, S. I., KEM, W. R. and PAPKE, R. L., 1995, Characterization of a series of anabaseine-derived compounds reveals that the 3-(4)-dimethyl-aminocinnamylidine derivative is a selective agonist at neuronal nicotinic a7/125 I-a-bungarotoxin receptor subtypes. Molecular Pharmacology, 47, 164–171.
   PubMed Web of Science ®Google Scholar
• FLOCKHART, D. A., 1995, Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19. Clinical Pharmacokinetics, 29 (Suppl. 1), 45–52.
   Google Scholar
• HUNTER, B. E., DE FIBRE, C. M., PAPKE, R. L., KEM, W. R. and MAYER, E. M., 1994, A novel nicotinic agonist facilitates induction of long-term potentiation in the rat hippocampus. Neuroscience Letters, 168, 130–134.
   PubMed Web of Science ®Google Scholar
• KITAGAWA, H., MoRrYAmA, A., TAICENOUCHI, T., WESNES, K., KRAMER, W. and CLODY, D. E., 1998, Phase I studies of GTS-21 to assess the safety, tolerability, PK and effects on measures of cognitive function in normal volunteers. Neurobiology of Aging, 19 (Suppl. 2), S182.
   Google Scholar
• Ko, J. W., SUKHOVA, N., THACICER, D., CHEN, P. and FLOCKHART, D. A., 1997, Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metabolism and Disposition, 25, 853–862.
   PubMed Web of Science ®Google Scholar
• MACHINIST, J. M., MAYER, M. D., SHET, M. S., FERRERO, J. L. and RODRIGUES, A. D., 1995, Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193. Drug Metabolism and Disposition, 23, 1163–1174.
   PubMed Web of Science ®Google Scholar
• MAHNIR, V., LIN, B., PROKAI -TATRAI, K. and KEM, W. R., 1998, Pharmacokinetics and urinary excretion of DMXBA (GTS-21), a compound enhancing cognition. Biopharmaceutics and Drug Disposition, 19, 147–151.
   PubMed Web of Science ®Google Scholar
• MATHEWS, J. M., ETHERIDGE, A. S., RAY-MIER, J. H., BLACK, S. R., PULLIAM, D. W. JR and BUCHER, J. R., 1998, Selective inhibition of cytochrome P450 2E1 in vivo and in vitro with trans-1,2-dichloroethylene. Chemical Research in Toxicology, 11, 778–785.
   Google Scholar
• MEYER, E. M, KING, M. A. and MEYERS, C., 1998, Neuroprotective effects of 2,4-dimethoxybenzylidene anabaseine (DMXB) and tetrahydroaminoacridine (THA) in neocortices of nucleus basalis lesioned rats. Brain Research, 786, 252–254.
   PubMed Web of Science ®Google Scholar
• NANRI, M., YAMAMOTO, J., MIYAKE, H. and WATANABE, H., 1998, Protective effect of GTS-21, a novel nicotinic receptor agonist, on delayed neuronal death induced by ischemia in gerbils. Japanese Journal of Pharmacology, 76, 23–29.
   PubMedGoogle Scholar
• NEWTON, D. J., WANG, R. W. and Lu, A. Y. H., 1995, Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154–158.
   PubMed Web of Science ®Google Scholar
• SHAH, V. P., MIDHA, K. K., DIGHE, S., MCGILVERAY, I. J., SKELLY, J. P., YACOBI, A., LAYLOFF, VISWANATHAN, C. T., COOK, C. E., MuDowALL, R. D., PITTMAN, K. A. and SPECTOR, S., 1992, Analytical methods validation: Bioavailability, bioequivalence, and pharmacokinetic studies. Journal of Pharmaceutical Sciences, 81, 309–312.
   Google Scholar
• SHIMOHAMA S ., GREENWALD, D. L., S HAFRON, D. H., AKAIKA, A., MAEDA, T., KANEKO, S ., KIMURA, J SIMPKINS, C. E., DAY, A. L. and MEYER, E. M., 1998, Nicotinic a7 receptors protect against glutamate neurotoxicity and neuronal ischemic damage. Brain Research, 779, 359–363.
   Google Scholar
• SUMMERS, K. L., KEM, W. R. and GIACOBINI, E., 1997, Nicotinic agonist modulation of neurotransmitter levels in the rat frontoparietal cortex. Japanese Journal of Pharmacology, 74, 139–146.
   PubMedGoogle Scholar
• TASSANEEYAKUL W., BIRKETT, D. J., VERONESE, M. E., McMANus, M. E., TURKEY, R. H, QUATTROCHI L. C., GELBOIN, H. V. and MINERS, J. 0., 1993, Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. Journal of Pharmacology and Experimental Therapeutics, 265, 401–407.
   Google Scholar
• ZOLTEWICZ, J. A., PROKAI -TATRAI, K., BLOOM, L. B. and KEm, W. R., 1993, Long range transmission of polar effects in cholinergic 3-arylideneanabaseines. conformations calculated by molecular modelling. Heterocycles, 35, 171–179.
   Google Scholar